Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy.

Affiliation

Department of Respiratory Medicine, Affiliated Cancer Hospital of Zhengzhou University, China. Electronic address: [Email]

Abstract

This study aims to understand the effects and long-term survival of 1st generation epithelial growth factor receptor tyrosine kinase inhibitors(EGFR-TKI)or platinum-based chemotherapy as first-line therapy in advanced lung adenocarcinoma patients with uncommon EGFR mutations.

Keywords

Epithelial growth factor receptor,Lung adenocarcinoma,Tyrosine kinase inhibitors,Uncommon mutation,

OUR Recent Articles